miR-708-5p targets oncogenic prostaglandin E2 production to suppress a pro-tumorigenic phenotype in lung cancer cells

Nicholas J. Monteleone and Carol S. Lutz

Department of Microbiology, Biochemistry, and Molecular Genetics, Rutgers Biomedical & Health Sciences, New Jersey Medical School, School of Graduate Studies, Newark, NJ 07103, USA

Correspondence to: Carol S. Lutz, email: lutzcs@njms.rutgers.edu

Keywords: miR-708-5p; miR-708; lung cancer; COX-2; mPGES-1

Received: March 27, 2020 Accepted: May 14, 2020 Published: June 30, 2020

ABSTRACT

Many cancers maintain an inflammatory microenvironment to promote their growth. Lung cancer is of particular importance, as it is the deadliest cancer worldwide. One inflammatory pathway commonly dysregulated in cancer is the metabolism of arachidonic acid (AA) by Cyclooxygenase-2 (COX-2) and microsomal Prostaglandin E Synthase 1 (mPGES-1) into Prostaglandin E2 (PGE2). While researchers have identified PGE2’s pro-tumorigenic functions, the mechanisms governing overexpression of COX-2 and mPGES-1 are incompletely understood. MicroRNAs (miRNAs) are important post-transcriptional regulators commonly dysregulated in cancer. Interestingly, miR-708-5p (miR-708) is predicted to target both COX-2 and mPGES-1. In this study, we show that high miR-708 expression is associated with survival rates in lung squamous cell carcinoma patients. miR-708 also represses PGE2 production by suppressing both COX-2 and mPGES-1 expression in lung cancer cells. miR-708 regulation of COX-2 and mPGES-1 is mediated through targeting of their 3’ untranslated regions (UTRs). Moreover, miR-708 decreases proliferation, survival, and migration of lung cancer cells, which can be partially attributed to miR-708’s inhibition of PGE2 signaling. Lastly, we identify novel miR-708 predicted targets and possible regulators of miR-708 expression in lung cancer. Collectively, these data demonstrate that dysregulated miR-708 expression contributes to exacerbated PGE2 production, leading to an enhanced pro-tumorigenic phenotype in lung cancer cells.

INTRODUCTION

Lung cancer is the most common cancer, with more than 2.09 million lung cancer cases worldwide in 2018 [1]. More importantly, lung cancer is the deadliest cancer in the world, with more than 1.79 million lung cancer related deaths in 2018 [1]. $12.1 billion is spent on lung cancer care in the United States every year, yet survival rates are exceedingly low, with only 17% of patients living 5 years post-diagnosis [1–3]. Late detection, resistance, and a limited treatable population result in metastasis and death. Therefore, it is imperative to develop novel methods to identify, distinguish, and more efficaciously treat lung cancer patients.

Lung cancer is a collection of several distinct subtypes, with non-small cell lung cancer (NSCLC) accounting for 85% of all lung tumors [4]. Within NSCLC, there are two major histological subtypes: adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). There are other subtypes within NSCLC, but these two subtypes account for over 90% of NSCLCs. While all NSCLC patients are characterized as either subtype, identification techniques are insufficient. Although tumors are differentiated by subtype, LUAD and LUSC are generally treated with the same chemotherapeutics. Newer techniques are identifying genomic and epigenomic markers to distinguish between subtypes, yet these findings have had limited translation to the clinic [5]. The World Health Organization also recategorized NSCLC subtypes in 2015, but researchers and clinicians have not fully understood how subtypes respond to different therapies [6]. Thus, it is necessary to discover novel biomarkers that better distinguish NSCLC subtypes to improve efficacious outcomes.
Historically, chemotherapeutics have been developed to target cancer cells without regard to other cells found within the tumor microenvironment (TME). Newly approved treatments are beginning to take into consideration the broader TME by mitigating the pro-tumor effects of certain immune cells, or by activating the immune system to attack cancer cells [7, 8]. Inflammatory enzymes and their metabolites govern much of the signaling between cancerous and immune cells, and over-activation of inflammatory pathways pre-dispose individuals to carcinogenesis as well as promote tumor growth, invasion, and immune evasion [9, 10]. These pathways are normally tightly regulated, but in lung cancer there is exacerbated expression of many inflammatory-related genes.

One commonly dysregulated inflammatory pathway in lung cancer is the arachidonic acid metabolic (AA) pathway [11]. AA is a 20-carbon poly-unsaturated fatty acid found within the membranes of the cell. AA is released from cellular membranes into the cytosol by the Phospholipase A2 family of enzymes, which then can be metabolized by Cyclooxygenase-2 (COX-2), the rate limiting enzyme of prostaglandin production, to prostaglandin H2 (PGH2) [12, 13]. The downstream enzyme microsomal prostaglandin E synthase 1 (mPGES-1) metabolizes PGH2 into biologically active Prostaglandin E2 (PGE2) [14, 15]. In normal lung epithelial cells, COX-2 and mPGES-1 proteins are not detected [16]. However, in lung cancer cells, our lab and others have shown that COX-2 and mPGES-1 are overexpressed (Supplementary Figure 1 [16]). Multiple studies have shown that COX-2 overexpression in lung cancer patients decreased survival rates, and long-term use of COX inhibitors decrease cancer risk [17, 18]. COX-2 inhibitors also synergized with chemotherapeutics and PD-1 blocking antibodies to re-sensitize resistant lung cancer cells, decrease metastasis, and eliminate immune evasion [19–22]. While COX-2 and mPGES-1 have been associated with cancer, PGE2 is the signaling molecule responsible for promoting tumorigenesis.

Molecularly, COX-2/mPGES-1 derived PGE2 acts in an autocrine and paracrine fashion by activating 1 of 4 PGE2 receptors to modulate mitogen-activated protein kinases (MAPK), phosphoinositide-3-kinase (PI3K), and β-catenin signaling cascades [23–31]. Phenotypically, PGE2 is integrally involved in inflammatory responses, the wound healing process, and stem cell renewal [32]. In the context of cancer, PGE2 has been shown to promote cancer cell proliferation, invasion, angiogenesis, and survival [23–31, 33–44]. Although PGE2 regulates cancer cell growth directly, its most profound role may be in regulating the TME immune composition. PGE2 has been shown to modulate macrophage phenotype, inhibit CD8+ T-cell, Treg, and natural killer (NK) cell activation, prevent dendritic cell (DC) maturation, and promote recruitment of myeloid-derived suppressor cells (MDSCs), Treg, and Th2 cells [14, 45–47]. Given PGE2’s diverse pro-tumorigenic functions, inhibiting PGE2 is an attractive therapeutic intervention.

Lipid-signaling molecules are difficult to target, therefore researchers have focused on inhibiting PGE2 production. COX-1/2 and COX-2 specific inhibitors used in numerous clinical oncology trials have produced varying results [48]. These inhibitors have dangerous gastrointestinal and cardiovascular side effects, respectively, limiting their adoption into the clinic. Researchers have recently been developing mPGES-1 inhibitors to suppress PGE2 production [49, 50]. While mPGES-1 small molecule inhibitors have shown tumor suppressive characteristics, safe and efficacious PGE2-inhibiting therapies remain enigmatic.

Recently, scientists have begun using ribonucleic acid (RNA)-based therapies to treat cancer [51]. One major class of regulatory RNAs is microRNA (miRNA). miRNAs are small, noncoding RNAs that negatively regulate target gene expression. They typically carry out this function through imperfect base pairing with the 3′ untranslated region (UTR) of target mRNAs, resulting in translational stalling or transcript degradation [52]. Dysregulated miRNA expression or function is often seen in cancers, resulting in overexpression of oncogenes and/or underexpression of tumor suppressors [53, 54].

One recently discovered miRNA identified as being misexpressed in multiple diseases is miR-708-5p (miR-708). Interestingly, miR-708 is predicted to target both COX-2 and mPGES-1 3′ UTRs [55]. Based on its validated targets, miR-708 is considered to be a pro-apoptotic miRNA [56]. It directly targets survival, growth, migratory, and immunosuppressive genes [56–62]. miR-708 also indirectly regulates expression of genes involved in PI3K signaling, cell cycle progression, epithelial-mesenchymal transition (EMT), and cancer stemness [56]. In lung cancer, two studies have differing conclusions on miR-708’s function. First, it was shown that miR-708 acted as an oncogenic miRNA in lung cancer by targeting TMEM88, a negative regulator of WNT signaling [63]. The second group discovered that low miR-708 expression in lung cancer patients was associated with increased metastasis [64]. In the same study, miR-708 restoration prevented lung cancer metastasis in vivo by suppressing pro-survival p21 expression [64]. Lastly, researchers determined that miR-708 inhibited lung cancer stem cell traits through modulation of Wnt/β-catenin signaling [65]. These opposing results create confusion as to the role of miR-708 in lung cancer. In this study, we aim to decipher novel miR-708 targets, and suggest a solution to the controversy on whether miR-708 is an oncogenic or tumor suppressive miRNA in lung cancer.

Here, we demonstrate that miR-708 expression is correlated with survival in LUSC patients. miR-708 is also expressed less in multiple lung cancer cell lines, and...
is inversely correlated with COX-2/mPGES-1 expressions in LUSC patients. Next, we show miR-708 directly targets the COX-2 and mPGES-1 3′ UTRs, resulting in decreased COX-2 and mPGES-1 protein expression, leading to diminished PGE₂ levels. miR-708 restoration suppresses proliferation, survival, and migration of lung cancer cells. miR-708-induced changes can partially be contributed to its targeting of pro-oncogenic PGE₂ signaling. Lastly, we investigate novel miR-708 regulated pathways in LUSC. Together, these data support the conclusion that miR-708 is acting as a tumor suppressive miRNA in NSCLC cells through targeting of pro-tumorigenic AA signaling.

RESULTS

miR-708 expression correlates with survival in LUSC patients

To determine the clinical relevance of miR-708 in lung cancer patients, we analyzed data from The Cancer Genome Atlas (TCGA) using the TCGA-assembler 2 R software package [66]. TCGA data is a collection of RNA-Seq, miR-Seq, methylation, proteomic, and clinical data categorized by cancer type. TCGA analysis revealed that miR-708 expression did not have a significant effect on NSCLC survival rates (Figure 1A, \( p = .063, \text{HR} = 0.80 \ [0.63–1.01], n = 864 \)). Further analysis on NSCLC subtypes revealed that high miR-708 expression was significantly associated with higher survival rates in LUSC patients (Figure 1B, \( p < .01, \text{HR} = 0.66 \ [0.48–0.91], n = 424 \)), while miR-708 had no association with survival in LUAD patients (Figure 1C, \( p = .98, \text{HR} = 0.99 \ [0.69–1.41], n = 442 \)). We also analyzed LUSC patients by their Tumor Node Metastasis (TNM) Staging, which showed no significant difference in miR-708 expression between stages (Supplementary Figure 2). These data suggest miR-708 may have a tumor suppressive role in LUSC tumors regardless of TNM stage, but no effect on survival in LUAD cancers.

miR-708 expression is lower in lung cancer cells in comparison to non-cancerous lung cells

We next examined expression of miR-708 in normal and lung cancer cells to determine if our cell lines faithfully replicated clinical data. We investigated expression of miR-708 in normal (Human Bronchial Epithelial Cells [HBECs], Beas2b) and lung cancer (A549, H1299, H1975) cell lines (Figure 1D) by RT-qPCR. HBECs are primary human lung cells, while Beas2bs are immortalized non-cancerous lung epithelial cells. miR-708 expression was 3-10 fold higher in HBECs compared to lung cancer cell lines (Figure 1D, \( p < .001, n = 3 \)). The same trend was seen in Beas2b cells as compared to A549, H1299, and H1975 cells (\( p < .01, n = 3 \)). We also examined ODZ4 expression, as miR-708 is found within intron 1 of the ODZ4 gene [67]. ODZ4’s expression correlated with miR-708 expression, suggesting expression of miR-708 is under the control of the ODZ4 promoter (Figure 1D). Lower miR-708 expression in lung cancer cells appears to be through promoter methylation, as 5-Azacytidine, a non-methylatable cytidine analog, increased miR-708 expression in A549 cells (Figure 1E, \( p < .01, n = 3 \)). This conclusion is supported by prior research that revealed miR-708 expression is primarily regulated through the ODZ4 promoter, which was also done in A549 cells and repeated in primary lung tumor samples [65, 68]. In addition, ODZ4 mRNA survival curves correlated with miR-708 survival curves in NSCLC, LUAD, and LUSC patients (Supplementary Figure 3). Lastly, Table 1 shows that ODZ4 mRNA expression was highly correlated with miR-708 in NSCLC (\( p = .692, R^2 = .478, p = 4.90 \times 10^{-14} \)), LUSC (\( p = .646, R^2 = .416, p = 1.61 \times 10^{-60} \)), and LUAD (\( p = .536, R^2 = .286, p = 1.76 \times 10^{-40} \)). These data indicate that promoter methylation of the ODZ4 gene is most likely responsible for the lower miR-708 expression in lung cancer cells.

miR-708 suppresses PGE₂ production by targeting the COX-2 and mPGES-1 3′ UTRs

AA can be metabolized into prostaglandins or leukotrienes, as illustrated in Figure 2A. Leukotrienes are important for immune cell signaling and differentiation, while prostaglandins have various homeostatic, developmental, and immune related functions [69, 70]. Although both COX-1 and COX-2 produce the short-lived intermediate PGH₂, COX-1 is generally coupled with homeostatic prostaglandin (PG) levels, while COX-2 and mPGES-1 are associated with inducible levels of PGF₂ production [55, 71]. Therefore, in the context of disease, COX-2 and mPGES-1 are generally accepted as the cyclooxygenase and synthase associated with pathogenic PG production.

Interestingly, miR-708 is predicted to target both the COX-2 and mPGES-1 3′ UTRs (Figure 2B, 2C). Clinically, miR-708 expression was inversely correlated with COX-2 and mPGES-1 mRNA expression in NSCLC and LUSC tumors (Table 1). A549 cells had inverse COX-2 and mPGES-1 protein expression compared to miR-708 ([16], Supplementary Figure 1, Figure 1D). Given these data, we tested the ability of miR-708 to regulate COX-2 and mPGES-1 protein expression. Western blot analysis of A549 cells transiently transfected with mock or a scrambled negative control miRNA (NC miR) revealed no change in COX-2 and mPGES-1 protein levels (Figure 3A and 3B). On the other hand, COX-2 and mPGES-1 proteins were specifically downregulated in A549 cells transfected with synthetic miR-708 (Figure 3A and 3B). FLAP served as a negative control, as it is a protein within the AA pathway, but not a miR-708 target. Next, we measured A549 PGE₂ secretion by enzyme-
linked immunosorbent assay (ELISA). Mock and NC miR treated cells retained high PGE$_2$ levels, while addition of miR-708 significantly reduced PGE$_2$ levels (Figure 3C, \( p < .001, n = 3 \)). Taken together, these data suggest that miR-708’s ability to suppress PGE$_2$ levels is through repression of COX-2 and mPGES-1 proteins in A549 cells. While the evidence supports miR-708 targeting of COX-2 and mPGES-1, it remains unknown whether miR-708’s suppression is direct or indirect.

To determine if miR-708 is directly targeting the COX-2 and mPGES-1 3’ UTRs, we performed luciferase reporter assays using the pLightSwitch_3UTR Renilla luciferase reporter vector containing the full length COX-2 or mPGES-1 3’ UTR. 3’ UTR-containing vectors were co-transfected with mock, synthetic miR-708, or NC miR, and data were normalized to the GAPDH 3’ UTR and total protein concentration. miR-708 significantly reduced luciferase activity in wild-type COX-2 (Figure 4B, \( p < .0001, n \geq 3 \) and mPGES-1 (Figure 4D, \( p < .05, n \geq 3 \) 3’ UTRs compared to the mock and NC miR treatments. Next, we mutated the miR-708 predicted binding site in each construct, specifically in the seed sequence (Figure 4A and 4C). We repeated our mock, synthetic miR-708, and NC miR treatments in HeLa cells transiently transfected

---

**Figure 1:** miR-708 expression correlates with survival rates and is underexpressed in lung cancer cell lines. Kaplan–Meier plots from TCGA data measuring the effects of high (blue) or low (red) miR-708 expression in (A) Non-small cell lung cancer (NSCLC) \( (p = .063, \text{HR} = 0.80 \ [0.63–1.01], n = 864) \), (B) Lung squamous cell carcinoma (LUSC) \( (p < .01, \text{HR} = 0.66 \ [0.48–0.91], n = 424) \), and (C) Lung adenocarcinoma (LUAD) \( (p = .98, \text{HR} = 0.99 \ [0.69–1.41], n = 442) \) on patient survival rates. The bottom of each graph indicates the number of patients at risk for each time point. (D) RT-qPCR of mature miR-708 (blue) and ODZ4 (red) mRNA expression across numerous lung cell lines. miR-708 expression was normalized to U6 snRNA while ODZ4 mRNA was normalized to GAPDH mRNA. \( (** p < .01, (***) p < .001, n = 3 \). (E) RT-qPCR of mature miR-708 expression +/− 10 uM 5-Azacytidine for 48 hours in A549 cells. Data were normalized to U6 snRNA. \( (**) p < .01, n = 3 \).
with the COX-2 and mPGES-1 mutated 3’ UTR constructs. Luciferase reporter assays revealed that miR-708 treatment of the mutated miR-708 binding site containing constructs reverted miR-708 induced changes in COX-2 (Figure 4B, \( p < .0001, n \geq 3 \)) and mPGES-1 (Figure 4D, \( p < .05, n \geq 3 \)) 3’ UTR luciferase activity back to mock and NC miR levels. These data suggest that miR-708 is indeed directly targeting the COX-2 and mPGES-1 3’ UTRs.

**miR-708 represses a pro-tumorigenic phenotype in lung cancer cells**

Given miR-708’s ability to directly target COX-2/mPGES-1 derived PGE_2’s pro-tumorigenic functions, we next examined the capacity of miR-708 to regulate lung cancer cell proliferation, survival, and invasion. First, we performed a Water Soluble Tetrazolium Salts (WST)-1 assay on mock, NC miR, or synthetic miR-708 treated lung cancer cells (A549s, H1299, H1975, and H1373; Figure 5A). WST-1 is converted by mitochondrial dehydrogenases into a colored dye, directly measuring metabolic activity, which correlates with cellular proliferation and viability. Metabolic activity was significantly decreased in miR-708 treated lung cancer cells as compared to mock and NC miR treated samples (Figure 5A, \( p < .05, n \geq 3 \)), suggesting that miR-708 was suppressing proliferation or increasing cellular death in these lung cancer cells.

Next, we analyzed miR-708-induced phenotypic changes through AA signaling inhibition. It is important to determine each target’s contribution to phenotypic changes, as miRNAs are simultaneously suppressing numerous transcripts. To restore AA signaling in A549 cells, we added exogenous PGE_2. As seen in Figure 5B,

---

**Figure 2: miR-708 is predicted to target the AA pathway.** (A) Diagram depicting the metabolism of arachidonic acid (AA) into PGE_2/other prostaglandins and LTC_4/leukotrienes by cyclooxygenases or Lipoxygenases, respectively. Enzymes within the pathway are represented in red. AA pathway short-lived intermediates and mature eicosanoids are represented in black. (*) Indicate genes with putative miR-708 binding sites. (B, C) Sequence and predicted miR-708 binding sites to the full length wild-type COX-2 (B) and mPGES-1 (C) 3’ UTRs. miR-708 seed sequence is indicated in red, straight lines indicate matched pairing while dotted lines represent G-U mismatch pairing.
Table 1: miR-708 expression is correlated with COX-2, mPGES-1, and ODZ4 expressions in lung cancer patients

| Subtype | Gene   | miRNA  | Correlation | Adj. R^2   | p value       |
|---------|--------|--------|-------------|------------|---------------|
| NSCLC   | PTGS2  | miR-708| -0.0847     | 0.00621    | 0.006571      |
| NSCLC   | PTGES  | miR-708| -0.0892     | 0.00698    | 0.004228      |
| NSCLC   | ODZ4   | miR-708| 0.692       | 0.478      | 4.90E-147     |
| LUAD    | PTGS2  | miR-708| 0.015       | -0.00168   | 0.7308        |
| LUAD    | PTGES  | miR-708| -0.048      | 0.000402   | 0.2716        |
| LUAD    | ODZ4   | miR-708| 0.536       | 0.286      | 1.76E-40      |
| LUSC    | PTGS2  | miR-708| 0.0916      | 0.00641    | 0.04018       |
| LUSC    | PTGES  | miR-708| -0.126      | 0.0139     | 0.004761      |
| LUSC    | ODZ4   | miR-708| 0.646       | 0.416      | 1.61E-60      |

TCGA mRNA/miRNA data showing correlation coefficient, adjusted R^2, and significance between miR-708 and COX-2 (PTGS2), mPGES-1 (PTGES), or ODZ4 mRNA expression in NSCLC (n = 864), LUAD (n = 442), and LUSC (n = 424). Bold italic font indicates a significant negative correlation; italic font represents a significant positive correlation; bold font indicates no significant correlation.

Figure 3: The AA pathway is regulated by miR-708 in lung cancer cells. (A) Western blot analysis of proteins from A549 cells that were transiently transfected with 12.5 nM miR-708, 25 nM miR-708, or 25 nM NC miR for 48 hours. GAPDH served as a loading control, and FLAP served as a negative control. (B) Quantification of western blot from (A), n ≥ 3. (C) PGE2 ELISA of supernatant collected from mock, NC miR, and miR-708 treated A549 cells. Data were normalized to total protein. GAPDH served as a loading control. All western blots are representative of 3 independent experiments. (***p < .001, (****) p < .0001, n ≥ 3.)
Figure 4: miR-708 directly targets COX-2 and mPGES-1 3’ UTRs. (A) Sequence and predicted miR-708 binding site to the full length wild-type COX-2 3’ UTR containing luciferase construct (top), as well as the sequence of the mutated miR-708 binding site within the COX-2 3’ UTR luciferase construct (bottom). miR-708 seed sequence is indicated in red, straight lines indicate matched pairing while dotted lines represent G-U mismatch pairing. (B) Relative Renilla luciferase activity of the full length wild-type COX-2 3’ UTR (blue) or mutated miR-708 binding site (orange). Relative Renilla luciferase activities were measured in response to mock, NC miR, or synthetic miR-708 treatment in HeLa cells. Data were normalized to Renilla luciferase constructs containing the wild-type GAPDH 3’ UTR for each treatment. All samples were also normalized to total protein. (C) Sequence and predicted miR-708 binding site to the full length wild-type mPGES-1 3’ UTR containing luciferase construct (top), as well as the sequence of the mutated miR-708 binding site within the mPGES-1 3’ UTR luciferase construct (bottom). miR-708 seed sequence is indicated in red, straight lines indicate matched pairing while dotted lines represent G-U mismatch pairing. (D) Relative Renilla luciferase activity of the full length wild-type mPGES-1 3’ UTR (blue) or mutated miR-708 binding site (orange). Relative Renilla luciferase activities were measured in response to mock, NC miR, or synthetic miR-708 in HeLa cells. Data were normalized to Renilla luciferase constructs containing the wild-type GAPDH 3’ UTR for each treatment. All samples were also normalized to total protein concentration. (*) p < .05, (***p < .0001, COX-2 (p < .0001, mPGES-1 (p < .05, n ≥ 3.
PGE\textsubscript{2} addition to miR-708 treated A549 cells restored metabolic activity to mock/NC miR levels ($p < .05$, $n \geq 3$). These data suggest miR-708 suppression of COX-2 and mPGES-1 is having a tumor suppressive effect on lung cancer cell phenotype, but the exact hallmarks of cancer that miR-708 treatment is modulating remains obscure. While the WST-1 assay is helpful in identifying broad phenotypic changes, further analysis is necessary to establish if miR-708 is suppressing proliferation, survival, and migration in lung cancer cells.

To further investigate how miR-708 is influencing lung cancer cell phenotype, we performed Ki-67 staining to observe proliferation, Annexin V staining to detect apoptosis, and examined migration real-time using the xCelligence Real-Time Cell Analyzer (RTCA) assay. Ki-67 is commonly used marker found in proliferating cells [72]. To test proliferation in A549 cells, we used the FITC Mouse Anti-Ki-67 kit, a flow cytometry assay that uses an anti-Ki-67 antibody in conjunction with propidium iodide (PI) staining to determine proliferation and cell cycle states. First, we measured differences in Ki-67 positivity (Figure 6A–6C). Our IgG control stained negative, while about 88% of mock and 86% of NC miR treated A549 cells stained positive for Ki-67 (Figure 6A–6C, $n = 3$). On the other hand, miR-708 treated samples had significantly less Ki-67 + cells (~57%) compared to mock and NC miR samples (Figure 6A–6C, $p < .0001$, $n \geq 3$). Addition of PGE\textsubscript{2} to miR-708 treated samples increased the Ki-67 positive population, although this rescue was not significantly different from miR-708 treated samples (Figure 6A–6C). This indicates that while miR-708 reduces proliferation its anti-proliferative characteristics cannot be solely attributed to regulation of PGE\textsubscript{2} signaling (Figure 6A–6C).

Beyond looking at the proliferative populations, dual Ki-67 staining with PI allows us to investigate cell cycle stage. PI is an intercalating fluorescent dye used to measure DNA content. Using PI alone, one could...
determine 3 different stages of the cell cycle: G0/G1, S phase, and G2/M phase. As seen in Figure 6D, there were no significant differences observed amongst treatments within each cell cycle stage. While PI is useful, it is limited, as it cannot distinguish between G0 and G1 populations. To do this, we used co-staining Ki-67 flow cytometry data to distinguish between these groups. G0 cells are in a non-dividing state, whereas G1 cells are actively proliferating. Using Ki-67 and PI together, Figure 6E illustrates how to identify different cell cycle stages. G0 cells are Ki-67/- low PI, G1 are Ki-67+/low PI, cells in S phase are Ki-67+/intermediate PI, and G2/M cells are Ki-67+/high PI. Given these populations, we determined that miR-708 triggered cells to enter the G0 state compared to mock or NC miR treated samples (Figure 6F–6H and 6J, p < .05, n ≥ 3). The increase in G0 miR-708 treated cells corresponded to a significant decrease in G1 cells as well, with no significant differences seen in S or G2/M phases (Figure 6F–6H and 6J, p < .05, n ≥ 3). Lastly, PGE₂ addition to miR-708 treated A549 cells did not significantly change cell cycle stage, albeit miR-708 + PGE₂ treated cells were partially restored to the G1 state (Figure 6I and 6J, p = n. s., n ≥ 3). This suggests that miR-708 repression of COX-2/mPGES-1 derived PGE₂ is involved in miR-708’s anti-proliferative effects, but is not a major contributor. While proliferation is an important hallmark of cancer, survival is also important for tumor growth.

miR-708 was previously shown to target survivin and pro-survival p21 in cancer [59, 64]. Given these findings, we next examined the ability of miR-708 to alter survival in lung cancer cells. To achieve this, we used the Annexin V antibody to measure changes in phosphatidylserine (PS) externalization, a marker for apoptosis [73]. Healthy cells stain negative for Annexin V, as PS is located on the inner-leaflet of the plasma membrane. During apoptosis, cells externalize PS, which can be detected by Annexin V. We determined there was a significant increase in Annexin V positive A549 cells in miR-708 treated samples compared to mock or NC miR (Figure 7A and 7B, p < .01, n ≥ 3). PGE₂ addition to miR-708 treated samples significantly decreased the number of PS positive cells (Figure 7A and 7B, p < .05, n ≥ 3). Therefore, miR-708’s suppression of COX-2/mPGES-1 derived PGE₂ is partly responsible for changes in survival rates.

While Annexin V positive cells are undergoing apoptosis, it does not differentiate between early or late apoptosis. To achieve this distinction we co-stained cells with 4’,6-diamidino-2-phenylindole (DAPI), an impermeable DNA dye. Early apoptotic cells are DAPI negative but Annexin V positive. Late apoptotic and dead cells stain positive for DAPI and Annexin V, as the plasma membrane becomes permeable at this stage of apoptosis. In Figure 7, flow cytometry of dually stained A549 cells treated with miR-708 revealed an increase in the early (bottom right quadrant) and late (top right quadrant) apoptotic populations as compared to mock and NC miR samples (Figure 7C–7E). We quantified the percent of total cells in the early and late apoptotic quadrants for each sample, as seen in Figure 7G and 7H. miR-708 significantly increased the percentage of early apoptotic cells compared to mock or NC miR treated cells (Figure 7G, p < .01, n ≥ 3) while PGE₂ addition to miR-708 treated samples did not significantly decrease early apoptotic events (Figure 7G, p = .06, n ≥ 3). When we quantified late apoptotic events, miR-708 treated A549 cells also had a significant increase in late apoptosis (Figure 7H, p < .01, n ≥ 3). The percent of late apoptotic cells in miR-708 + PGE₂ treated samples was restored to mock and NC miR levels (Figure 7H, p < .01, n ≥ 3), indicating that miR-708 suppression of AA signaling may be somewhat responsible for miR-708’s pro-apoptotic characteristics. Apoptotic differences may not be as profound as desired due to the pro-apoptotic effect of miR-708. A normal, 50 nM transient transfection of miR-708, was too toxic, as cells died before analysis could be conducted. Therefore, we resorted to a lower dose that was effective, albeit with less prominent phenotypic changes. Together, these data suggest that miR-708 increases apoptosis in lung cancer cells, which can be partly attributed to miR-708’s targeting of COX-2/mPGES-1 derived PGE₂. Lastly, we tested miR-708’s ability to modulate cellular migration.

To directly measure cellular migration, we used the xCelligence RTCA. Briefly, the xCelligence RTCA is an instrument that can detect changes in migration using an electronically integrated Boyden chamber known as the CIM-16 plate. As cells pass from the upper chamber through a microporous membrane towards the chemoattractant containing lower chamber, differences in conductivity are measured and quantified. This measurement is known as the cellular index, which is directly correlated to cellular adherence. The xCelligence RTCA has the ability to take time course measurements, which are plotted as the cellular index over time. Thus, the xCelligence system has many advantages over a scratch test, as it can accurately measure and quantify migration. Using this system, we transiently transfected A549 cells with the following treatments: mock, 25 nM NC miR, 25 nM miR-708, and 25 nM miR-708 + 1 uM PGE₂. 24 hours after treatment, we plated treated cells onto the CIM-16 plate, and recorded migration rates for 48 hrs.

As seen in Figure 8, miR-708 treatment significantly decreased the cellular index (migration) of A549 cells compared to mock and NC miR samples (2-Way ANOVA: p < .0001, Welch’s corrected t-test p = .0002, n = 3; linear regression: p < .0001, n = 3). While there appears to be no significant difference in migration, comparing means differences at every time point (ANOVA) and slope variations (linear regressions), it was revealed that miR-708 significantly decreased migration rates in A549 cells. Interestingly, when we restored PGE₂ levels in miR-708 treated samples, there was a significant increase in migration rates compared to miR-708 treated samples.
Figure 6: miR-708 attenuates proliferation in A549 cells partially through targeting of AA signaling. (A) Representative histogram depicting the number of A549 cells that were Ki-67 negative (> 10^3) and positive (< 10^3) as measured by flow cytometry. For this figure, sample colors are as followed: mock (blue), 25 nM NC miR (red), 25 nM miR-708 (green), and 25 nM miR-708 + 1 uM PGE_2 (purple). A549 cells were exposed to an IgG Isotype control antibody (gray) or anti-Ki-67 antibody in transiently transfected mock, 25 nM NC miR, 25 nM miR-708, and 25 nM miR-708 + 1 uM PGE_2 samples 48 hours after treatment. (B) Representative overlay Ki-67 Histogram from (A) without the IgG control antibody data. (C) Quantification of the –/+ Ki-67 populations in various treatments from (B). (D) Quantification of cell cycle stages (G0/G1 phase, Synthesis [S] phase, G2 phase/Mitosis [M]) via PI staining by flow cytometry in transiently transfected mock, 25 nM NC miR, 25 nM miR-708, and 25 nM miR-708 + 1 uM PGE_2 A549 cells. (E) Representative smoothed graph showing cell cycle stage based on Ki-67 and PI staining. Blue represents low cell area density, while red indicates high cell area density. Boxes identify populations as followed: G0 is -Ki-67/low PI, G1 is +Ki-67/low PI, S is +Ki-67/Intermediate PI, G2/M is +Ki-67/High PI. (F–I) Representative cell cycle stage graphs of mock, 25 nM NC miR, 25 nM miR-708, or 25 nM miR-708 + 1 uM PGE_2 treated A549 cells evaluated by flow cytometry. (J) Quantification cell cycle stage of graphs from (F–I). (*) p < .05, (**) p < .01, (***) p < .0001, no significant difference (n. s.), n ≥ 3.
(Figure 8, 2-Way ANOVA: $p < .0001$, Welch’s corrected t-test $p < .0001$, $n = 3$; linear regression: $p < .0001$, $n = 3$). There was no difference in migration between mock, NC miR, and miR-708 + PGE$_2$ treated samples (Figure 8, n.s., $n \geq 3$). We limited our data collection to 28 hours, as data after that time point could be skewed by cellular proliferation. Given these data, we conclude that miR-708’s anti-migratory qualities are attributed to its suppression of COX-2/mPGES-1 derived PGE$_2$ in A549 cells.

**DISCUSSION**

Since the signing of the National Cancer Act in 1971, there has been much advancement in the treatment of cancer. Survival rates in breast, colon, and prostate cancers have increased dramatically due to improvements in detection and treatment of these cancers [74]. While lung cancer incidence rates have decreased dramatically since the 1990’s, survival rates have only modestly increased during this time [75]. Lung cancer is a complex collection of deadly diseases that are generally hard to detect and treat. Therefore, it is crucial to develop novel methods to identify, distinguish, and treat lung cancer.

In this study, we identified a miRNA with potent anti-tumorigenic effects in lung cancer cells. miR-708 has previously been described as being both oncogenic and tumor suppressive in lung cancer [63–65]. Therefore, we aimed to clarify the tumor suppressive or oncogenic functions of miR-708 in lung cancer cells. We discovered that miR-708 was underexpressed in lung cancer cells, and low miR-708 expression correlated with decreased survival in LUSC patients (Figure 1). Next, we showed miR-708 suppressed pro-tumorigenic PGE$_2$ production by...
directly repressing COX-2 and mPGES-1 expression in lung cancer cells (Figures 3 and 4). We also demonstrated that miR-708 decreases lung cancer cell metabolism (Figure 5), proliferation (Figure 6), survival (Figure 7), and migration (Figure 8). These effects were partially be attributed to miR-708’s targeting of COX-2/mPGES-1 derived PGE_2 (Figures 5–8). Together, these results suggest that miR-708 is a tumor suppressive miRNA in lung cancer cells. We hope these data will resolve confusion on the function of miR-708 in lung cancers. Although this study answered questions about the role of miR-708 in lung cancer, several questions remain.

First, why is miR-708 expression decreased in lung cancer cells compared to normal lung cells? As shown by our lab and others, it appears miR-708 expression is primarily suppressed through hypermethylation of the ODZ4 promoter in lung cancer (Figure 1E [65]). Alternatively, low miR-708 expression may be due to a loss of tumor suppressive transcription factors. Interestingly, miR-708’s expression in LUSC tumors is positively correlated with a majority of known miR-708 regulators (Supplementary Table 1). One pro-apoptotic transcription factor in particular, C/EBP homologous protein (CHOP), shares a very similar expression pattern as miR-708 in LUSC tumors. As seen in Supplementary Figure 4, TCGA data revealed high CHOP mRNA expression is associated with prolonged survival in LUSC patients (Supplementary Figure 4B, \( p = .014, \) HR = 0.67 [0.49–0.92] \( n = 424 \)). CHOP activity has been shown to be dysregulated in cancer through mutation and transcriptional suppression [76]. Therefore, repressed CHOP activity may be attributed to loss of miR-708 expression in lung cancer.

On the other hand, glucocorticoid receptor-alpha (GRα) mRNA expression is negatively correlated with miR-708 expression in LUSC tumors (Supplementary Table 1). While previous work indicates GRα positively regulates miR-708 expression in breast cancer, it was recently shown that prolonged GRα signaling suppresses CHOP activity in lung cancer [61, 77]. Thus, GRα inhibition of CHOP activity may lead to diminished miR-708 levels in LUSC tumors. While this proposed mechanism explains the data from Supplementary Table 1, further testing needs to be performed before conclusions can be made. Regardless, our work and the work of others provide a strong foundation for further exploring the therapeutic value of miR-708 in lung cancer [64, 65].

Several miRNAs are currently being tested in clinical trials, highlighting their therapeutic potential [78, 79]. While delivery remains an obstacle, miRNAs are attractive candidates for cancer treatment, as a single miRNA can target many genes (often of similar biological function) simultaneously [80]. Although we have shown that miR-708 can repress a pro-tumorigenic phenotype through suppression of AA signaling, we recognize that miRNAs have many targets. MiRNAs generally target hundreds of transcripts, making it difficult to attribute phenotypic effects to a single target or pathway. While we conclude that miR-708 suppression of COX-2/mPGES-1 derived PGE_2 has a significant effect on lung cancer cell proliferation, survival, and invasion, the tumor suppressive qualities of miR-708 are most likely a combinatory targeting of multiple oncogenic genes, including survivin,

Figure 8: miR-708 reduction of A549 cellular migration is mediated through the AA signaling pathway. Real-time analysis of A549 cell migration (cell index) over 28 hours using the xCelligence RTCA analyzer. For this figure, sample colors are as followed: mock (blue), 25 nM NC miR (red), 25 nM miR-708 (green), and 25 nM miR-708 + 1 μM PGE_2 (purple) treated A549 cells. Data were analyzed by 2-Way ANOVA and linear regression analysis to compare differences in means and slope, respectively. (***) \( p < .0001, \) (*) \( p = .0002, \) no significant difference (n. s.), \( n \geq 3. \)
p21, cFLIP, and AKT2 to just name a few [56–62]. Given the pleotropic effects of miRNAs, it is imperative to further investigate miR-708’s targetome.

Interestingly, miR-708 is predicted to target 5-Lipoxygenase (5-LO), another gene in the AA pathway, which is responsible for leukotriene production (Figure 9 [55]). As shown in Figure 9 and Supplementary Table 2, miR-708 expression is negatively correlated with expression of multiple AA pathway genes in LUSC tumors. Given these data, it is plausible miR-708 is a crucial negative regulator of AA signaling in general, not just pro-tumorigenic PGE2 signaling. It is not unprecedented, as researchers have shown that miR-146a represses both arms of AA signaling (cyclooxygenase and lipoxygenase) through targeting of COX-2 and 5-lipoxygenase activating protein (FLAP) [16, 81]. Clinicians are searching for viable dual inhibitors of prostaglandin and leukotriene production is, as one arm of AA signaling can rescue inhibition of the other arm, leading to compensatory signaling and resistance [82, 83]. To date, researchers have not been successful in creating efficacious and tolerable dual COX-2/5-LO small molecule inhibitors in the clinic [84]. Therefore, if miR-708 targets 5-LO and suppresses leukotriene signaling, it may be a novel means to more fully inhibit AA signaling.

Collectively, our findings suggest further study of miR-708 in lung cancer. Our data paired with previous studies highlight a potential value for miR-708 as a diagnostic in differentiating lung tumors, as well as a potential therapeutic intervention, particularly in lung squamous cell carcinomas. Our work has identified novel tumor suppressive miR-708 functions by suppressing oncogenic PGE2 production through targeting of COX-2 and mPGES-1. These findings could be the foundation for identifying novel miR-708 targets, as well as regulators of miR-708 expression in cancer. Moreover, our study highlights the need to better understand lung cancer biology to improve diagnosis and treatment of lung cancer, ultimately aiming to increase positive patient outcomes.

**MATERIALS AND METHODS**

**Mammalian cell culture**

A549, Beas2B, and HeLa cells (ATCC) were grown in Dulbecco’s Modified Eagle Medium (DMEM, MilliporeSigma, St. Louis, MO, USA), and H1975 and H1299 cells (ATCC) were grown in Roswell Park Memorial Institute-1640 Medium (RPMI, MilliporeSigma). All media were supplemented with 10%
miRNA and 5-Azacytidine treatments

A549 cells were seeded in 6-well plates at 3 × 10^4 cells per well. Synthetic versions of hsa-miR-708-5p and non-targeting miRNAs were purchased from (Horizon Discovery, Waterbeach, United Kingdom). Hsa-miR-708-5p mature miRNA sequence: 5′-AAGGAGCUUACAAUCUAGCUGGG-3′, accession #: MIMAT004926. Horizon Discovery’s miRIDIAN microRNA Mimic Negative Control #1 was used as a non-targeting miRNA. This miRNA has a scrambled sequence with no predicted targets in the human transcriptome. Twenty-four hours after seeding, A549 cells were transiently transfected with synthetic miRNAs at 25 nM (unless stated otherwise) using INTERFERin (Polyplus, Berkeley, CA, USA) according to the manufacturer’s protocol. Using the same seeding protocol, A549 cells were treated with 10 μM 5-Azacytidine (MilliporeSigma) in complete medium. Fresh media was added at the same time as the 5-Azacytidine treatment. Twenty-four hours after treatment, A549 cells were harvested and RNA was isolated. Quantitative real-time RT-PCR (qRT-PCR) was performed using the miScript SYBR Green PCR Kit (Qiagen). No template and no reverse transcriptase controls, as well as melt curve analysis were implemented to ensure samples/primers were not contaminated. Quantitative Comparative C_\text{T} (\Delta\Delta C_\text{T}) analysis was used to analyze gene expression changes relative to U6 snRNA/ miR-15a (miRNA) or GAPDH (mRNA). qRT-PCR data represent the average of ≥ 3 biological replicates. Each sample was measured with n ≥ 2 technical replicates per target gene per independent experiment.

Western blot analysis

Treated cells were washed with 1× PBS and lysed in RIPA buffer (50 mM Tris at pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.1% protease inhibitor). The cells supernatant were then centrifuged at 14000 × g for 15 min at 4°C. Protein concentration was determined using the DC Protein Assay (Bio-Rad, Hercules, CA, USA). 25 μg of protein were loaded onto 10% SDS-PAGE gels and transferred onto PVDF membrane (VWR) for 2 hours at 4°C. Blots were blocked with 5% non-fat milk + PBSt (5% non-fat dry milk, 1× PBS, 0.1% Tween-20 [MilliporeSigma]) for 1 hour at room temperature (RT). Primary antibody incubations against human COX-2 ([1:2000], 160112, Cayman Chemical, Ann Arbor, MI, USA), mPGES-1 ([1:1000], ab180589, Abcam), Survivin ([1:1000], ab76424, Abcam), FLAP ([1:1000], EPR5640, Abcam), GAPDH ([1:2500], HRP-6004, Proteintech, Rosemont, IL, USA), and Tubulin ([1:2500], HRP-6031, Proteintech) were performed overnight at 4°C per manufacturer’s recommended dilutions. Blots were washed with PBSt × 3 for 5 minutes each, then exposed to secondary HRP conjugated secondary antibodies (Goat anti-Mouse H+L [1:5000, 31460, Abcam], GAPDH ([1:1000], ab76424, Abcam), FLAP ([1:1000], EPR5640, Abcam), GAPDH ([1:2500], HRP-6004, Proteintech, Rosemont, IL, USA), and Tubulin ([1:2500], HRP-6031, Proteintech) for 1 hour at RT. Blots were developed using Clarity Western ECL Substrate (Bio-Rad) on the ChemiDoc MP Imaging system (Bio-Rad). Western blot images are representative of ≥ 3 biological replicates.

Plasmids

The pLightSwitch_3UTR Renilla luciferase reporter vector and a clone containing the full human COX-2, mPGES-1, and GAPDH 3′ UTRs were purchased from SwitchGear Genomics (Carlsbad, CA, USA). COX-2 and mPGES-1 3′UTR mutant plasmids were also obtained from SwitchGear Genomics. Inserted 3′ UTRs were sequenced to ensure 3′ UTRs of interest were faithfully replicated while performing midi-preps on plasmids (data not shown). Site-directed mutational sequences can be replicated while performing midi-preps on plasmids (data not shown). Site-directed mutational sequences can be replicated while performing midi-preps on plasmids (data not shown). Site-directed mutational sequences can be replicated while performing midi-preps on plasmids (data not shown). Site-directed mutational sequences can be replicated while performing midi-preps on plasmids (data not shown).
after seeding, cells were transfected 50 nM synthetic miRNA (miR-708 or NC miR) using INTERFERin (Polyplus) per manufacturer’s protocol. The next morning cells were transfected with the appropriate luciferase-containing plasmid using LipoD293 (Signagen, Rockville, MD, USA) per manufacturer’s protocol. Six hours later media was replaced. Twenty-four hours later cells were washed with cold 1× PBS and lysed with 1× Passive Lysis Buffer (Promega, Madison, WI, USA). Luminescence was measured using the Renilla-Glo luciferase assay system (Promega) per manufacturer’s protocol using the SpectraMax M2 plate reader (Molecular Devices). Renilla luciferase activity was normalized to total protein concentration as determined by Bradford assay. Luminescence was also normalized from samples transfected with pLightSwitch_GAPDH 3’ UTR under the same miRNA condition which were also normalized to total protein concentration. All assays represent the average of ≥ 3 biological replicates.

Enzyme-Linked Immunosorbent Assay (ELISA) Analysis

A549 PGE\textsubscript{2}, levels in cell culture media were analyzed using the PGE\textsubscript{2} Express ELISA Kit (500141, Cayman Chemical, Ann Arbor, MI, USA) per manufacturer’s instructions. Media was removed and cells were incubated for 20 min with serum-free media containing 10 µM arachidonic acid (Cayman Chemical) in serum-free DMEM. Collected media was centrifuged at 5000 g × 10 min, 4°C. Media was transferred to new tubes, then centrifuged at 2,000 g × 10 min, 4°C before being transferred to new tubes. Before analysis, samples were diluted 10× with 1× ELISA buffer. Absorbance was read using the SpectraMax M2 plate reader (Molecular Devices, San Jose, CA, USA). PGE\textsubscript{2}, levels were measured in technical duplicates, normalized to total protein levels, and are an average of ≥ 3 biological replicates.

Phenotypic assays

WST-1

WST-1 Cell Proliferation Assay (Cayman Chemical) was performed in clear walled 96-well plates per the manufacturer’s protocol. Cells were seeded at 1 × 10\textsuperscript{4} cells per well. Absorbance was read at 450 nm using the SpectraMax M2 plate reader (Molecular Devices). Media was aspirated and total protein was collected. Data were normalized to total protein, and represent the average of ≥ 3 biological replicates.

Ki-67 staining

Proliferation was measured in A549 cells using the FITC Mouse Anti-Ki-67 Kit (BS Biosciences, San Jose, CA, USA). A549 cells were plated in 60 mm dishes at 4 × 10\textsuperscript{5} cells per plate. Twenty-four hours later cells were mock or synthetic miRNA (25 nM) treated and returned to grow for 48 hours. Cells were washed with cold 1× PBS then trypsinized (0.25% Trypsin-EDTA, Corning, NY, USA). Cells were then fixed per the manufacturer’s protocol and put in −20°C for a minium of 2 hours. Following the manufacturer’s guidelines, Ki-67 and propidium iodide (PI) were added to 1 × 10\textsuperscript{6} cells and incubated. Samples also include an IgG isotype control that stains negative for Ki-67. Flow Cytometry was performed on the BD FACS Celesta machine (BD Biosciences), recording 30,000 events. Data were analyzed using FlowJo software (BD Biosciences). The alive population was selected from each sample (forward versus side scatter). Further analysis revealed Ki-67 +/− populations, as well as cell cycle stage as previously done by Kim & Sederstrom [85].

Annexin V staining

Apoptosis was measured in A549 cells using the Annexin V Apoptosis Detection I Kit (BS Biosciences). As previously described A549 cells were plated in 60 mm dishes at 4 × 10\textsuperscript{4} cells per plate. Twenty-four hours later cells were mock or synthetic miRNA (25 nM) treated and returned to grow for 48 hours. Cells were washed with cold 1× PBS then trypsinized (0.25% Trypsin-EDTA, Corning, NY, USA). Cells were centrifuged and resuspended per manufacturer’s protocol. Following resuspension, appropriate amounts of phycoerythrin (PE) labeled Annexin V and DAPI were added to 2 × 10\textsuperscript{5} cells and incubated for 15 minutes in the dark. Samples also included an unstained negative control and boiled positive control. Flow Cytometry was performed on the BD FACS Celesta machine (BD Biosciences), recording 20,000 events. Data were analyzed using FlowJo software (BD Biosciences). Analysis revealed alive, early apoptotic, and late apoptotic/necrotic populations as previously shown by Wallberg et al. [86].

Cell migration assay

Cell migration was analyzed using the xCelligence Real-Time Cell Analyzer (Acea Biosciences, San Diego, CA, USA). To measure cellular migration, we used the CIM-Plate 16 system, which is a real-time quantifiable Transwell system. Briefly, A549 cells were seeded in 6-well plates and treated as previously described in the “miRNA, 5-Azacytidine, PGE\textsubscript{2}, and Celecoxib Treatments” section. Wells were assembled per manufacturer’s instructions, with bottom wells having FBS-containing media. 24 hours after treatment, cells were trypsinized for 1–2 minutes using 0.05% Trypsin, 0.53 mM EDTA (Corning, NY, USA). Cells were counted, spun down, and resuspended at 3 × 10\textsuperscript{5} cells/mL. 3 × 10\textsuperscript{5} cells were added to the top well of each plate. For each treatment there was a serum-free well to control for random cellular movement. Once assembled and cells added, plates were placed in an incubator housing the xCelligence Real-Time Cell Analyzer for 48 hours. Migration measurements were taken every 10 minutes.
Data were normalized to serum-free media samples. All treatments represent the average of ≥ 3 biological replicates. To analyze migration data for significance, we used two statistical approaches in Prism 7. First, we measured differences between treatments using 1-way ANOVA. For post-hoc tests, we used Welch-corrected t-tests to determine significance between treatments. Next, we analyzed slope differences between treatments via linear regression analysis. This combinatory statistical approach strengthened our migratory conclusions.

**Bioinformatic and statistical analysis**

miR-708 predicted targeting sequences were obtained from mirorna.org. Predicted targets were also analyzed using miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/php/index.php). The Cancer Genome Atlas (TCGA) was mined using the TCGA-assembler 2 R software package [66]. Lung Adenocarcinoma (LUAD) and Lung Squamous Cell Carcinoma (LUSC) RNA-Seq (gene. normalized_RNAseq, gene_RNAseq) and miR-Seq (mir_GA, hg19mirbase20, mir_HiSeq, hg19, mirbase20) were downloaded by TCGA-assembler 2 and analyzed on R using internal lab written software. Clinical data were matched with mir-708 expression data and analyzed using the R packages “survminer” and “survival”. Analyzed data were graphed using “ggplot2.” Significance and confidence intervals were determined using the “survminer” internal pvalue and conf. int functions. These functions compute significance, hazard ratios, and confidence intervals using the log-rank test and 95% upper/lower bands. Inquiries about lab written code can be emailed to carollutzlab@gmail.com. NSCLC data is a combination of both LUAD and LUSC datasets. The data are expressed as the mean +/- SEM. All non-clinical data are expressed as the mean +/- SD. We used Prism 7 software to perform one-way ANOVA and Student’s t-test to determine significant differences. Where indicated, the non-parametric tests were used to determine statistical significance. Inverse correlation studies used the Pearson product-moment correlation coefficient to determine the correlation value, r, and adjusted R^2. P-value was determined by using the correlation value, r, and the sample size. P-values less than 0.05 were considered significant.

**Abbreviations**

AA: Arachidonic Acid; cDNA: Complementary DNA; CEL: Celecoxib; CHOP: C/EBP Homologous Protein; COX-2: Cyclooxygenase-2; DAPI 4′,6-diamidino-2-phenylindole; DC: Dendritic Cell; DMEM: Dulbecco’s Modified Eagle’s Medium; ELISA: Enzyme-Linked Immunosorbent Assay; EMT: Epithelial-Mesenchymal Transition; FLAP: 5-Lipoxygenase Activating Protein; GRα: Glucocorticoid Receptor-Alpha; HBEC: Human Bronchial Epithelial Cells; LUAD: Lung Adenocarcinoma; LUSC: Squamous Carcinoma of the Lung; MAPK: Mitogen-Activated Protein Kinases; MDSCs: Myeloid-Derived Suppressor Cells; miR-708: miR-708-5p; miRNA: microRNAs; mPGES-1: microsomal Prostaglandin E Synthase 1; NC miR: Negative Control miRNA; NK: Natural Killer; NSCLC: Non-Small Cell Lung Cancer; PE: Phycocerythrin; PG: Prostaglandin; PGE2: Prostaglandin E2; PGG2: prostaglandin H2; PI: Propidium Iodide; PI3K: Phosphoinositide-3-Kinase; PS: Phosphatidylserine; RNA: Ribonucleic Acid; RPMI: Roswell Park Memorial Institute-1640; RTCA: Real-Time Cell Analyzer; TCGA: The Cancer Genome Atlas; TME: Tumor Microenvironment; TNM: Tumor Node Metastasis; UTR: Untranslated Region.

**Author contributions**

Dr. Carol S. Lutz is the corresponding author for this manuscript. Nicholas J. Monteleone did the work and writing.

**ACKNOWLEDGMENTS**

We would like to thank the labs of Dr. Batish, Dr. Birge, and Dr. Parveen for sharing supplies, equipment, ideas, and friendship. We would also like to thank past and present members of the Lutz lab for their insight and feedback.

**CONFLICTS OF INTEREST**

Authors have no conflicts of interest to declare.

**FUNDING**

This research was conducted under the following grants: the New Jersey Commission on Cancer Research (NJCCR, DFHS18CRF003) and the National Institute of Health (NIH, RO1AR069044).

**REFERENCES**

1. World Health Organization. Top 10 Causes of Death (Madr), 2014. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
2. Howlader NNA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, et al. 2012 Lung Cancer Facts. In: Alliance LC, ed.h https://seer.cancer.gov/archive/csr/1975_2009_pops09/.
3. US National Institutes of Health NCI. SEER Cancer Statistics Review, 1975–2011, 2011. https://seer.cancer.gov/archive/csr/1975_2011_results_merged/topic_annualrates.pdf.
4. American Cancer Society. Cancer Facts and Figures, 2014, 2014. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2014.html.
5. Huang T, Li J, Zhang C, Hong Q, Jiang D, Ye M, Duan S. Distinguishing Lung Adenocarcinoma from Lung Squamous Cell Carcinoma by Two Hypomethylated and Three Hypermethylated Genes: A Meta-Analysis. PLoS One. 2016; 11:e0149088. https://doi.org/10.1371/journal.pone.0149088. [PubMed]

6. Inamura K. Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. Front Oncol. 2017; 7:193. https://doi.org/10.3389/fonc.2017.00193. [PubMed]

7. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powdril JD, Carvalho RD, Sosman JA, Atkins MB, Lenning PD, Spigel DR, Antonia SJ, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366:2443–2454. https://doi.org/10.1056/NEJMoa1200690. [PubMed]

8. Brahmer JR, Pardoll DM. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res. 2013; 1:85–91. https://doi.org/10.1158/2326-6066.CIR-13-0078. [PubMed]

9. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454:436–444. https://doi.org/10.1038/nature07025. [PubMed]

10. Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med. 2000; 248:171–183. https://doi.org/10.1046/j.1365-2966.2000.00742.x. [PubMed]

11. Yokouchi H, Kanazawa K. Revisiting the role of COX-2 inhibitor for non-small cell lung cancer. Transl Lung Cancer Res. 2015; 4:660–664. https://doi.org/10.3978/j.issn.2218-6751.2015.04.03. [PubMed]

12. Hla T, Bishop-Bailey D, Liu CH, Schaefers HJ, Trifan OC. Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol. 1999; 31:551–557. https://doi.org/10.1016/S1357-2725(98)00152-6. [PubMed]

13. Radmark O, Werz O, Steinhiber D, Samuelsson B. 5-Lipoxgenase: regulation of expression and enzyme activity. Trends Biochem Sci. 2007; 32:332–341. https://doi.org/10.1016/j.tibs.2007.06.002. [PubMed]

14. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010; 10:181–193. https://doi.org/10.1038/nrc2809. [PubMed]

15. Yokomizo T, Izumi T, Shimizu T. Leukotriene B4: metabolism and signal transduction. Arch Biochem Biophys. 2001; 385:231–241. https://doi.org/10.1006/abbi.2000.2168. [PubMed]

16. Cornett AL, Lutz CS. Regulation of COX-2 expression by miR-146a in lung cancer cells. RNA. 2014; 20:1419–1430. https://doi.org/10.1261/rna.044149.113. [PubMed]

17. Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology. 2009; 17:55–67. https://doi.org/10.1007/s10787-009-8049-8. [PubMed]

18. Jiang H, Wang J, Zhao W. Cox-2 in non-small cell lung cancer: a meta-analysis. Clin Chim Acta. 2013; 419:26–32. https://doi.org/10.1016/j.cca.2013.01.012. [PubMed]

19. Sung MW, Lee DY, Park SW, Oh SM, Choi JJ, Shin ES, Kwon SK, Ahn SH, Kim YH. Celecoxib enhances the inhibitory effect of 5-FU on human squamous cell carcinoma proliferation by ROS production. Laryngoscope. 2017; 127:E117–E23. https://doi.org/10.1002/lary.26399. [PubMed]

20. Boutaud O, Sosa IR, Amin T, Orman D, Adler D, Hwang HS, Crews BC, Milne G, Harris BK, Hoeckema M, Knollmann BC, Lammers PE, Marnett LJ, et al. Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis. Cancer Prev Res (Phila). 2016; 9:855–865. https://doi.org/10.1158/1940-6207.CAPR-16-0094. [PubMed]

21. Zelenay S, van der Veen AG, Bottcher JP, Snelgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais R, Zecada SA, Sahai E, Reis e Sousa C. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell. 2015; 162:1257–1270. https://doi.org/10.1016/j.cell.2015.08.015. [PubMed]

22. Prima V, Kaliberova LN, Kaliberov S, Curiel DT, Kusmartsev S. COX2/pGEX1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proc Natl Acad Sci U S A. 2017; 114:1117–1122. https://doi.org/10.1073/pnas.1612920114. [PubMed]

23. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dothedwala M, Dubinett SM. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res. 2005; 65:6275–6281. https://doi.org/10.1158/0008-5472.CAN-05-0216. [PubMed]

24. Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res. 2005; 65:1822–1829. https://doi.org/10.1158/0008-5472.CAN-04-3671. [PubMed]

25. Ito H, Duxbury M, Benoit E, Clancy TE, Zinner MJ, Ashley SW, Whang EE. Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res. 2004; 64:7439–7446. https://doi.org/10.1158/0008-5472.CAN-04-1177. [PubMed]

26. Pan MR, Hou MF, Chang HC, Hung WC. Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J Biol Chem. 2008; 283:11155–11163. https://doi.org/10.1074/jbc.M710038200. [PubMed]

27. Liou JY, Ellent DP, Lee S, Goldsby J, Ko BS, Matijevic N, Huang JC, Wu KK. Cyclooxygenase-2-derived prostaglandin e2 protects mouse embryonic stem cells from apoptosis. Stem Cells. 2007; 25:1096–1103. https://doi.org/10.1634/stemcells.2006-0505. [PubMed]
28. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, Das SK, Dey SK, DuBois RN. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell. 2004; 6:285–295. https://doi.org/10.1016/j.ccr.2004.08.011. [PubMed]

29. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A. 2006; 103:1492–1497. https://doi.org/10.1073/pnas.0510562103. [PubMed]

30. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998; 58:362–366. [PubMed]

31. Poligone B, Baldwin AS. Positive and negative regulation of NF-kappaB by COX-2: roles of different prostaglandins. J Biol Chem. 2001; 276:38658–38664. https://doi.org/10.1074/jbc.M106599200. [PubMed]

32. Nakanishi M, Rosenberg DW. Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol. 2013; 35:123–137. https://doi.org/10.1007/s00281-012-0342-8. [PubMed]

33. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Naramiya S, Oshima M, Taketo MM. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med. 2001; 7:1048–1051. https://doi.org/10.1038/nm901-1048. [PubMed]

34. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, Tani K, Kobayashi M, Maruyama T, Kobayashi K, Ohuchida S, Sugimoto Y, Naramiya S, et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 2002; 62:28–32. [PubMed]

35. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Ushikubi F, Naramiya S, Sugimura T, Wakabayashi K. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 1999; 59:5093–5096. [PubMed]

36. Amano H, Hayashi I, Endo H, Kitasato H, Yamashina S, Maruyama T, Kobayashi M, Satoh K, Narita M, Sugimoto Y, Murata T, Yoshimura H, Naramiya S, Majima M. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med. 2003; 197:221–232. https://doi.org/10.1084/jem.20021408. [PubMed]

37. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999; 99:335–345. https://doi.org/10.1016/S0092-8674(00)81664-5. [PubMed]

38. Castellone MD, Teramoto H, Williams BO, Drucey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science. 2005; 310:1504–1510. https://doi.org/10.1126/science.1116221. [PubMed]

39. Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, Richmond A, Strieter R, Dey SK, DuBois RN. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med. 2006; 203:941–951. https://doi.org/10.1084/jem.20052124. [PubMed]

40. Abdl-Majid RM, Marshall JS. Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J Immunol. 2004; 172:1227–1236. https://doi.org/10.4049/jimmunol.172.2.1227. [PubMed]

41. Battersby S, Sales KJ, Williams AR, Anderson RA, Gardner S, Jabbour HN. Seminal plasma and prostaglandin E2 up-regulate fibroblast growth factor 2 expression in endometrial adenocarcinoma cells via E-series prostanooid-2-receptor-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase pathway. Hum Reprod. 2007; 22:36–44. https://doi.org/10.1093/humrep/dei328. [PubMed]

42. Tanaka S, Tatsuguchi A, Futagami S, Gudis K, Wada K, Seo T, Mitsui K, Yonezawa M, Nagata K, Fujimori S, Tsukui T, Kishida T, Sakamoto C. Monocyte chemotactrant protein 1 and macrophage cyclooxygenase 2 expression in colon adenoma. Gut. 2006; 55:54–61. https://doi.org/10.1136/gut.2004.059824. [PubMed]

43. Nakayama T, Mutsuga N, Yao L, Tosato G. Prostaglandin E2 promotes degranulation-independent release of MCP-1 from mast cells. J Leukoc Biol. 2006; 79:95–104. https://doi.org/10.1189/jlb.0405226. [PubMed]

44. Salcedo R, Zhang X, Young HA, Michael N, Wasserman K, Ma WH, Martins-Green M, Murphy WJ, Oppenheim JJ. Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood. 2003; 102:1966–1977. https://doi.org/10.1182/blood-2002-11-3400. [PubMed]

45. Olesch C, Sha W, Angioni C, Sha LK, Acaf E, Patrignani P, Jakobsson PJ, Radeke HH, Grosch S, Geisslinger G, von Knethen A, Weigert A, Brune B. MPGES-1-derived prostaglandin E2 up-regulates CD80 expression on tumor-associated macrophages correlated with late stage of lung cancer. J Exp Med. 2014; 214:297–306. https://doi.org/10.1186/1756-9966-30-62. [PubMed]

46. Olesch C, Sha W, Angioni C, Sha LK, Acaf E, Patrignani P, Jakobsson PJ, Radeke HH, Grosch S, Geisslinger G, von Knethen A, Weigert A, Brune B. MPGES-1-derived prostaglandin E2 suppresses CD80 expression on tumor-associated macrophages correlated with late stage of lung cancer. J Exp Med. 2014; 214:297–306. https://doi.org/10.1186/1756-9966-30-62. [PubMed]

47. Li Q, Liu L, Zhang Q, Liu S, Ge D, You Z. Interleukin-17 Indirectly Promotes M2 Macrophage Differentiation through Stimulation of COX-2/PGE2 Pathway in the Cancer Cells. Cancer Res Treat. 2014; 46:297–306. https://doi.org/10.4049/crt.2014.46.3.297. [PubMed]

48. Wang R, Lu M, Zhang J, Chen S, Luo X, Qin Y, Chen H. Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. J Exp Clin Cancer Res. 2011; 30:62. https://doi.org/10.1186/1756-9966-30-62. [PubMed]

49. Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K. Cyclooxygenase-2 in cancer: A review. J Cell Physiol. 2019; 234:5683–5699. https://doi.org/10.1002/jcp.27411. [PubMed]
49. Bergqvist F, Ossipova E, Idborg H, Raouf J, Checa A, Englund K, Englund P, Khoonsari PE, Kultima K, Wheelock CE, Larsson K, Korotkova M, Jakobsson PJ. Inhibition of mPGES-1 or COX-2 Results in Different Proteomic and Lipidomic Profiles in A549 Lung Cancer Cells. Front Pharmacol. 2019; 10:636. https://doi.org/10.3389/fphar.2019.00636. [PubMed]

50. Chang HH, Meuillet EJ. Identification and development of mPGES-1 inhibitors: where we are? Future Med Chem. 2011; 3:1909–1934. https://doi.org/10.4155/fmc.11.136. [PubMed]

51. Ha TY. MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease. Immune Netw. 2011; 11:135–154. https://doi.org/10.4110/in.2011.11.3.135. [PubMed]

52. Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Curr Biol. 2014; 24:R762–R776. https://doi.org/10.1016/j.cub.2014.06.043. [PubMed]

53. Lutz CS, Cornett AL. Regulation of genes in the arachidonic acid metabolic pathway by RNA processing and RNA-mediated mechanisms. Wiley Interdiscip Rev RNA. 2013; 4:593–605. https://doi.org/10.1002/wrna.1183. [PubMed]

54. Monteleone NJ, Lutz CS. miR-708-5p: a microRNA with emerging roles in cancer. Oncotarget. 2017; 8:71292–71316. https://doi.org/10.18632/oncotarget.19772. [PubMed]

55. Robin TP, Smith A, McKinsey E, Reaves L, Jedlicka P, Ford HL. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miR-708, resulting in increased cell survival and chemoresistance. Mol Cancer Res. 2012; 10:1098–1108. https://doi.org/10.1158/1541-7786.MCR-12-0086. [PubMed]

56. Girardot M, Pecquet C, Boukour S, Knoops L, Ferrant A, Subramanian S, Kannan MS. MicroRNA-708 regulates CD38 expression through signaling pathways JNK MAP kinase and PTEN/AKT in human airway smooth muscle cells. Respir Res. 2014; 15:107. https://doi.org/10.1186/s12931-014-0107-0. [PubMed]

57. Saini S, Majid S, Shahryari V, Hirata H, Tanaka Y, Daihya R. MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res. 2011; 71:6208–6219. https://doi.org/10.1158/0008-5472.CAN-11-0073. [PubMed]

58. Saini S, Majid S, Shahryari V, Arora S, Yamamura S, Chang I, Zaman MS, Deng G, Tanaka Y, Daihya R. miRNA-708 control of CD44(+) prostate cancer-initiating cells. Cancer Res. 2012; 72:3618–3630. https://doi.org/10.1158/0008-5472.CAN-12-0540. [PubMed]

59. Lin KT, Yeh YM, Chuang CM, Yang SY, Chang JW, Sun SP, Wang YS, Chao KC, Wang LH. Glucocorticoids mediate induction of microRNA-708 to suppress ovarian cancer metastasis through targeting Rap1B. Nat Commun. 2015; 6:5917. https://doi.org/10.1038/ncomms6917. [PubMed]

60. Dileepan M, Jude JA, Rao SP, Walseth TF, Panettieri RA, Harris CC, Yang P, Jen J. Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res. 2012; 18:3658–3667. https://doi.org/10.1158/1078-0432.CCR-11-2857. [PubMed]

61. Jang JS, Jeon HS, Sun Z, Aubry MC, Tang H, Park CH, Rakhsan F, Schultz DA, Kolbert CP, Lupu R, Park JY, Rakhshan F, Schultz DA, Kolbert CP, Lupu R, Park JY, Harris CC, Yang P, Jen J. Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res. 2012; 18:3658–3667. https://doi.org/10.1158/1078-0432.CCR-11-2857. [PubMed]

62. Dileepan M, Jude JA, Rao SP, Walseth TF, Panettieri RA, Harris CC, Yang P, Jen J. Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res. 2012; 18:3658–3667. https://doi.org/10.1158/1078-0432.CCR-11-2857. [PubMed]

63. Wei L, Jin Z, Yang S, Xu Y, Zhu Y, Ji Y. TCGA-assembler 2: software pipeline for retrieval and processing of TCGA/CPTAC data. Bioinformatics. 2018; 34:1615–1617. https://doi.org/10.1093/bioinformatics/btx812. [PubMed]

64. Behrmann S, Acosta-Alvear D, Walter P. A CHOP-regulated microRNA controls rhodopsin expression. J Cell Biol. 2011; 192:919–927. https://doi.org/10.1083/jcb.201010055. [PubMed]

65. Behrmann S, Acosta-Alvear D, Walter P. A CHOP-regulated microRNA controls rhodopsin expression. J Cell Biol. 2011; 192:919–927. https://doi.org/10.1083/jcb.201010055. [PubMed]

66. Senthil Kumar KJ, Gokila Vani M, Hsieh HW, Lin CC, Liao JW, Chueh PJ, Wang SY. MicroRNA-708 activation by glucocorticoid receptor agonists regulate breast cancer stem-like phenotypes through Repressing Wnt/beta-catenin Signaling. Clin Cancer Res. 2018; 24:1748–1760. https://doi.org/10.1158/1078-0432.CCR-17-1169. [PubMed]

67. Dennis EA, Norris PC. Eicosanoid storm in infection and inflammation. Nat Rev Immunol. 2015; 15:511–523. https://doi.org/10.1038/nri3859. [PubMed]

68. Behrmann S, Acosta-Alvear D, Walter P. A CHOP-regulated microRNA controls rhodopsin expression. J Cell Biol. 2011; 192:919–927. https://doi.org/10.1083/jcb.201010055. [PubMed]

69. Behrmann S, Acosta-Alvear D, Walter P. A CHOP-regulated microRNA controls rhodopsin expression. J Cell Biol. 2011; 192:919–927. https://doi.org/10.1083/jcb.201010055. [PubMed]

70. Behrmann S, Acosta-Alvear D, Walter P. A CHOP-regulated microRNA controls rhodopsin expression. J Cell Biol. 2011; 192:919–927. https://doi.org/10.1083/jcb.201010055. [PubMed]

71. Behrmann S, Acosta-Alvear D, Walter P. A CHOP-regulated microRNA controls rhodopsin expression. J Cell Biol. 2011; 192:919–927. https://doi.org/10.1083/jcb.201010055. [PubMed]
72. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182:311–322. https://doi.org/10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9. [PubMed]

73. Fadok VA, Bratton DL, Frasch SC, Warner ML, Henson PM. The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell Death Differ. 1998; 5:551–562. https://doi.org/10.1038/sj.cdd.4400404. [PubMed]

74. American Cancer Society. Cancer Facts & Figures, 2019. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf.

75. Jones GS, Baldwin DR. Recent advances in the management of lung cancer. Clin Med (Lond). 2018; 18:s41–s46. https://doi.org/10.7861/clinmedicine.18-2-s41. [PubMed]

76. Madden E, Logue SE, Healy SJ, Manie S, Samali A. The role of the unfolded protein response in cancer progression: From oncogenesis to chemoresistance. Biol Cell. 2019; 111:1–17. https://doi.org/10.1011/boc.201800050. [PubMed]

77. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007; 7:41–51. https://doi.org/10.1038/nri1995. [PubMed]

78. Hosseinahli N, Aghapour M, Duijf PHG, Baradaran B. Treating cancer with microRNA replacement therapy: A literature review. J Cell Physiol. 2018; 233:5574–5588. https://doi.org/10.1002/jcp.26514. [PubMed]

79. Hanna J, Hossain GS, Kocera J. The Potential for microRNA Therapeutics and Clinical Research. Front Genet. 2019; 10:478. https://doi.org/10.3389/fgene.2019.00478. [PubMed]

80. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6:259–269. https://doi.org/10.1038/nrc1840. [PubMed]

81. Iacona JR, Monteleone NJ, Lutz CS. miR-146a suppresses 5-lipoxygenase activating protein (FLAP) expression and Leukotriene B4 production in lung cancer cells. Oncotarget. 2018; 9:26751–26769. https://doi.org/10.18632/oncotarget.25482. [PubMed]

82. Hubbard NE, Erickson KL. Role of 5′-lipoxygenase metabolites in the activation of peritoneal macrophages for tumoricidal function. Cell Immunol. 1995; 160:115–122. https://doi.org/10.1016/0008-8749(95)80016-C. [PubMed]

83. Park SW, Heo DS, Sung MW. The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells. Cell Oncol (Dordr). 2012; 35:1–8. https://doi.org/10.1007/s13402-011-0051-7. [PubMed]

84. Gautam S, Roy S, Ansari MN, Saedan AS, Saraf SA, Kaitwas G. DuCLOX-2/5 inhibition: a promising target for cancer chemoprevention. Breast Cancer. 2017; 24:180–190. https://doi.org/10.1007/s12282-016-0723-2. [PubMed]

85. Kim KH, Sederstrom JM. Assaying Cell Cycle Status Using Flow Cytometry. Curr Protoc Mol Biol. 2015; 111:28 6 1-6 11. https://doi.org/10.1002/0471142727.mb2806s111. [PubMed]

86. Wallberg F, Tenev T, Meier P. Analysis of Apoptosis and Necroptosis by Fluorescence-Activated Cell Sorting. Cold Spring Harb Protoc. 2016; 2016:pdbrprot087387. https://doi.org/10.1101/pdb.prot087387. [PubMed]